Innovent Biologics Inc Capital Reinvestment Ratio
Innovent Biologics Inc capital reinvestment ratio. Innovent Biologics Inc (6IB) has a Capital Reinvestment Ratio of 0.97x as of December 2020, meaning it reinvests 1% of its operating cash flow (€217.96 Million) in capital expenditures (€211.14 Million). See Innovent Biologics Inc (6IB) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Innovent Biologics Inc (2023–2025)
Capital reinvestment ratio of Innovent Biologics Inc from 2023 to 2025. This chart tracks Innovent Biologics Inc's Capital Reinvestment Ratio across 3 annual periods. See Innovent Biologics Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Innovent Biologics Inc Capital Reinvestment Ratio by Year (2023–2025)
Innovent Biologics Inc capital reinvestment ratio by year from 2023 to 2025. For the full cash flow conversion analysis, see Innovent Biologics Inc (6IB) cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.07x | €10.00 Billion | €683.27 Million | ▼ -94.8% |
| 2024 | 1.33x | €1.29 Billion | €1.71 Billion | ▼ -85.8% |
| 2023 | 9.36x | €147.81 Million | €1.38 Billion | — |